Confluent raises funds for adhesion barrier trial:
This article was originally published in Clinica
Executive Summary
Biosurgery company Confluent Surgical, which develops products based on in situ polymerised hydrogel polymers and associated delivery systems, has raised $20m in a venture funding round. The Waltham, Massachusetts-based company's products are designed for post-surgical adhesion prevention and surgical sealing applications. The company will use the funds to support the completion of US trials into the SprayGel adhesion barrier, as well as extending the company's portfolio into surgical sealants for neuro, spine and cardiovascular surgery.